KR930006021A - 궤양 억제제의 제조방법 - Google Patents

궤양 억제제의 제조방법 Download PDF

Info

Publication number
KR930006021A
KR930006021A KR1019920016990A KR920016990A KR930006021A KR 930006021 A KR930006021 A KR 930006021A KR 1019920016990 A KR1019920016990 A KR 1019920016990A KR 920016990 A KR920016990 A KR 920016990A KR 930006021 A KR930006021 A KR 930006021A
Authority
KR
South Korea
Prior art keywords
formula
alkyl
cycloalkyl
treating
mixture
Prior art date
Application number
KR1019920016990A
Other languages
English (en)
Other versions
KR100242622B1 (ko
Inventor
스코트 호어너 로버트
제이. 프리드맨 조엘
세바스챤 어메이토 조셉
멩-한 류 토마스
이치로 신카이
엠. 웨인스톡 레오나드
Original Assignee
제임스 에프, 너턴
머크 앤드 캄파니, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제임스 에프, 너턴, 머크 앤드 캄파니, 인코포레이티드 filed Critical 제임스 에프, 너턴
Publication of KR930006021A publication Critical patent/KR930006021A/ko
Application granted granted Critical
Publication of KR100242622B1 publication Critical patent/KR100242622B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

치환된 피리딘 잔기 및 치환된 벤즈이미다졸 잔기 사이에 메틸설피닐 브릿지가 있는 궤양 억제제는 메틸티오브릿지가 있는 상응하는 화합물을 적합한 용매중에서 마그네슘 모노피옥시프탈레이트로 산화시켜 제조한다. 상기 반응은 방향족 탄화수소 용매중에서 수행할 수 있는데, 여기서 생성물은 반응 용액으로부터 결정화되고 여과에 의해 직접 분리할 수 있다.

Description

궤양 억제제의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 용매중의 일반식(Ⅱ)의 화합물의 혼합물을, 일반식(Ⅱ)의 화합물을 일반식(Ⅰ)의 화합물로 전환시키기에 충분한 양의 마그네슘 모노피옥시프탈레이트로 처리하는 단계를 포함함을 특징으로 하여, 일반식(Ⅰ)의 화합물을 제조하는 방법.
    상기 식(Ⅰ)에서 R1및 R3는 독립적으로 수소, C1-C8-알킬, C3-C8-사이클로알킬, C2-C8-플루오로알킬 및 C1-C8-알킬옥시중에서 선택된 것이며, R2는 수소, C1-C8알킬, C3-C8-사이클로알킬, C2-C8-플루오로알킬 및 C1-C8-알킬옥시 및-O-(CH2)n-R6{여기서, n은 1 내지 5이고, R6는 -O-(CH2)P-R6[여기서, p는 1내지 5이고, R7는 하이드록시, C1-C8알킬옥시, 아릴, 헤테로아릴, -O-아릴, C1-C8-아르알킬옥시, -O-(CH2)S-OR10(여기서, s는 1내지 5이고, R10은 수소, C1-C8알킬, C3-C8-사이클로알킬 및 아릴중에서 선택한 것이다), -할로겐 및-C(O)O-R10(여기서, R10은 상술한 바와같다)중에서 선택된 것이다], -피롤리디노닐-N-석신이미딜,{여기서, r은 0내지 2이고, R8은 C1-C8알킬, C3-C8-사이클로알킬, C1-C8-아르알킬, -C(O)O-C1-C8알킬, 피리딜, 푸라닐 및[여기서, X는 O,S 또는 NR10(여기서, R10은 상술한 바와 같다)이다]중에서 선택된 것이다},(여기서, R9은 아세톡시 C1-C8알킬 및 C3-C8-사이클로알킬중에서 선택된 것이다), OR10(여기서, R10은 상술한 바와 같다),(여기서, R11및 R12는 독립적으로 수소 및 C1-C8-알킬옥시중에서 선택된 것이다 및중에서 선택된 것이다)로부터 선택된 것이고, R4및 R5는 독립적으로 수소 및 C1-C8-알킬, C3-C8-사이클로알킬, CH2-C3-C8-사이클로알킬, C1-C8-알킬옥시, , C1-C8-플루오로알킬 및 CF3, -C(O)O-C2-C8-알킬중에서 선택된 것이며, Y는 CH 또는 N이다.
  2. 제1항에 있어서, 마그네슘 모노피옥시프탈레이트의 양이 일반식(Ⅱ)의 화합물 몰당 0.5 내지 0.7몰당량인 방법.
  3. 제1항에 있어서, 일반식(Ⅱ)의 화합물의 혼합물을 마그네슘 모노피옥시프탈레이트로 처리하는 단계 이전에 상기 혼합물을 알카리 염기로 처리하는 단계를 추가로 포함하는 방법.
  4. 제1항에 있어서, 용매가 톨루엔을 포함하는 방법.
  5. 용매중의 구조식(Ⅱa)의 파이르메타졸의 혼합물을, 상기 파이르메타졸을 구조식(Ⅰa)의 오메프라졸로 전환시키기에 충분한 양의 마그네슘 모노퍼옥시프탈레이트로 처리하는 단계를 포함함을 특징으로 하여, 구조식(Ⅰa)의 오메프라졸을 제조하는 방법.
  6. 제5항에 있어서, 용매가 톨루엔을 포함하는 방법.
  7. 제6항에 있어서, 용매가 톨루엔, 저 분자량의 알코올 및 물을 포함하는 방법.
  8. 제6항에 있어서, 오메프라졸을 여과에 의해 분리하는 단계를 추가로 포함하는 방법.
  9. 제8항에 있어서, 파이르메타졸의 혼합물을 마그네슘 모노퍼옥시프탈레이트로 처리하는 단계 이전에 상기 혼합물을 알칼리 염기로 처리하는 단계를 추가로 포함하는 방법.
  10. 제9항에 있어서, 알칼리 염기가 중탄산칼륨 및 중탄산나트륨중에서 선택되는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019920016990A 1991-09-20 1992-09-18 항궤양제의 제조방법 KR100242622B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US76456491A 1991-09-20 1991-09-20
US7/764,564 1991-09-20
US07/764,564 1991-09-20
US77787391A 1991-10-15 1991-10-15
US07/777,873 1991-10-15

Publications (2)

Publication Number Publication Date
KR930006021A true KR930006021A (ko) 1993-04-20
KR100242622B1 KR100242622B1 (ko) 2000-03-02

Family

ID=27117485

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920016990A KR100242622B1 (ko) 1991-09-20 1992-09-18 항궤양제의 제조방법

Country Status (18)

Country Link
US (1) US5391752A (ko)
EP (1) EP0533264B1 (ko)
JP (1) JPH0720956B2 (ko)
KR (1) KR100242622B1 (ko)
CN (1) CN1048729C (ko)
AT (1) ATE186535T1 (ko)
AU (1) AU649355B2 (ko)
CA (1) CA2078517C (ko)
DE (1) DE69230278T2 (ko)
DK (1) DK0533264T3 (ko)
ES (1) ES2143468T3 (ko)
GR (1) GR3032619T3 (ko)
IL (1) IL103156A (ko)
MX (1) MX9205333A (ko)
NZ (1) NZ244301A (ko)
PT (1) PT533264E (ko)
WO (1) WO1993006097A1 (ko)
YU (1) YU48291B (ko)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9002043D0 (sv) * 1990-06-07 1990-06-07 Astra Ab Improved method for synthesis
US5504082A (en) * 1992-06-01 1996-04-02 Yoshitomi Pharmaceutical Industries, Ltd. Pyridine compound and pharmaceutical compostions
WO1993024480A1 (en) * 1992-06-01 1993-12-09 Yoshitomi Pharmaceutical Industries, Ltd. Pyridine compound and medicinal use thereof
SE521100C2 (sv) * 1995-12-15 2003-09-30 Astra Ab Förfarande för framställning av en bensimidazolförening
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) * 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
CN1053444C (zh) * 1996-03-20 2000-06-14 常州市第四制药厂 奥美拉唑的一种精制方法
SE508669C2 (sv) * 1996-04-26 1998-10-26 Astra Ab Nytt förfarande
SK283805B6 (sk) 1996-09-09 2004-02-03 Slovakofarma, A. S. Spôsob prípravy omeprazolu
SE9704183D0 (sv) 1997-11-14 1997-11-14 Astra Ab New process
US6166213A (en) * 1998-08-11 2000-12-26 Merck & Co., Inc. Omeprazole process and compositions thereof
US6191148B1 (en) * 1998-08-11 2001-02-20 Merck & Co., Inc. Omerazole process and compositions thereof
US6852739B1 (en) 1999-02-26 2005-02-08 Nitromed Inc. Methods using proton pump inhibitors and nitric oxide donors
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
US6316020B1 (en) 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6262085B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6780880B1 (en) * 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
DE19951960C2 (de) 1999-10-28 2002-06-27 Gruenenthal Gmbh Verfahren zur Herstellung als Ulkustherapeutika geeigneter Benzimidazol-Derivate
WO2002062786A1 (en) 2001-02-02 2002-08-15 Teva Pharmaceutical Industries Ltd. Processes for the production of substituted 2-(2-pyridylmethyl) sulfinyl-1h-benzimidazoles
KR100783020B1 (ko) * 2001-03-23 2007-12-07 동아제약주식회사 2-메틸클로라이드 피리딘 유도체 및 이를 이용한 벤즈이미다졸 유도체의 제조 방법
IL159854A0 (en) * 2001-07-16 2004-06-20 Janssen Pharmaceutica Nv Improved process for preparing benzimidazole-type compounds
CA2472103A1 (en) * 2002-01-25 2003-08-07 Santarus, Inc. Transmucosal delivery of proton pump inhibitors
CA2493618A1 (en) * 2002-08-01 2004-02-12 Nitromed, Inc. Nitrosated proton pump inhibitors, compositions and methods of use
SE0203092D0 (en) * 2002-10-18 2002-10-18 Astrazeneca Ab Method for the synthesis of a benzimidazole compound
JP2006514108A (ja) 2002-12-19 2006-04-27 テバ ファーマシューティカル インダストリーズ リミティド パントプラゾールナトリウムの固体状態、それらの調製方法、及び公知のパントプラゾールナトリウム水和物の調製方法
RU2345075C2 (ru) * 2003-01-15 2009-01-27 Сипла Лимитед Способ получения фармацевтических средств и соединения, полученные данным способом
EP1603537A4 (en) * 2003-02-20 2009-11-04 Santarus Inc IMMEDIATE RELEASE OF OMEPRAZOLE ANTACIDAL COMPLEX WITH NEW FORMULATION FOR RAPID AND PROLONGED ELIMINATION OF GASTRIC ACID
ES2245277T1 (es) * 2003-03-12 2006-01-01 Teva Pharmaceutical Industries Limited Solidos cristalinos y amorfos de pantoprazol y procedimientos para su preparacion.
US7683177B2 (en) 2003-06-10 2010-03-23 Teva Pharmaceutical Industries Ltd Process for preparing 2-[(pyridinyl)methyl]sulfinyl-substituted benzimidazoles and novel chlorinated derivatives of pantoprazole
AU2004257864A1 (en) * 2003-07-18 2005-01-27 Santarus, Inc. Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
JP2006528181A (ja) * 2003-07-18 2006-12-14 サンタラス インコーポレイティッド 酸分泌を阻害するために有用な薬学的製剤ならびにそれらを作製および使用する方法
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
WO2005105799A1 (en) * 2004-04-28 2005-11-10 Altana Pharma Ag Dialkoxy-imidazopyridines derivatives
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) * 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CN1972928A (zh) * 2004-06-24 2007-05-30 阿斯利康(瑞典)有限公司 制备用于制备依美拉唑钠盐的结晶修饰物的新方法
GB0525710D0 (en) * 2005-12-17 2006-01-25 Pliva Hrvatska D O O An improved process for preparing of substituted 2-benzimidazolesulfoxide compounds
WO2008017020A2 (en) * 2006-08-03 2008-02-07 Dr. Reddy's Laboratories Limited Process for preparing proton pump inhibitors
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
EA200900985A1 (ru) 2007-01-31 2009-12-30 Крка, Товарна Здравил, Д. Д., Ново Место Способ получения оптически чистого омепразола
WO2010134099A1 (en) 2009-05-21 2010-11-25 Cadila Healthcare Limited One pot process for preparing omeprazole and related compounds
CN104203938A (zh) 2012-01-21 2014-12-10 朱比兰特生命科学有限公司 用于制备2-吡啶基甲基亚硫酰基苯并咪唑、它们的类似物和光学活性对映体的方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
US4483781A (en) * 1983-09-02 1984-11-20 The Procter & Gamble Company Magnesium salts of peroxycarboxylic acids
JPS6150978A (ja) * 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
JPS61178919A (ja) * 1985-02-04 1986-08-11 Banyu Pharmaceut Co Ltd ベンズイミダゾ−ル誘導体およびそれを含有する医薬
JPS62201884A (ja) * 1986-02-28 1987-09-05 Tokyo Tanabe Co Ltd ベンズイミダゾール誘導体及びその製造法
JPH0643426B2 (ja) * 1986-07-25 1994-06-08 東京田辺製薬株式会社 イミダゾ〔４，５−ｂ〕ピリジン誘導体、その製造法及びそれを含有する抗潰瘍剤
FI864046A (fi) * 1986-10-07 1988-04-08 Farmos Oy Foerfarande foer framstaellning av en terapeutiskt aktiv foerening.
FI90544C (fi) * 1986-11-13 1994-02-25 Eisai Co Ltd Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi
DE3722810A1 (de) * 1987-07-10 1989-01-19 Hoechst Ag Substituierte benzimidazole, verfahren zu deren herstellung, diese enthaltende pharmazeutische zubereitungen und deren verwendung
DK171989B1 (da) * 1987-08-04 1997-09-08 Takeda Chemical Industries Ltd Fremgangsmåde til fremstilling af 2-(2-pyridylmethylsulfinyl)-benzimidazoler
EP0390842A1 (de) * 1987-12-11 1990-10-10 Byk Gulden Lomberg Chemische Fabrik GmbH Neue benzimidazolderivate
SE8804629D0 (sv) * 1988-12-22 1988-12-22 Ab Haessle New therapeutically active compounds
SE8804628D0 (sv) * 1988-12-22 1988-12-22 Ab Haessle New compounds
FR2660313B1 (fr) * 1990-04-02 1992-07-03 Fournier Ind & Sante Nouveau sulfonyl-phenyl-betha-d-thioxylosides, leur procede de preparation et leur utilisation en therapeutique.

Also Published As

Publication number Publication date
CA2078517C (en) 2003-11-04
YU89492A (sh) 1995-10-03
KR100242622B1 (ko) 2000-03-02
DE69230278D1 (de) 1999-12-16
WO1993006097A1 (en) 1993-04-01
IL103156A (en) 1997-02-18
ES2143468T3 (es) 2000-05-16
ATE186535T1 (de) 1999-11-15
CA2078517A1 (en) 1993-03-21
JPH05213936A (ja) 1993-08-24
US5391752A (en) 1995-02-21
NZ244301A (en) 1994-08-26
DE69230278T2 (de) 2001-04-05
MX9205333A (es) 1993-07-01
IL103156A0 (en) 1993-02-21
EP0533264B1 (en) 1999-11-10
DK0533264T3 (da) 2000-05-15
YU48291B (sh) 1998-05-15
AU2520792A (en) 1993-03-25
CN1048729C (zh) 2000-01-26
AU649355B2 (en) 1994-05-19
EP0533264A1 (en) 1993-03-24
JPH0720956B2 (ja) 1995-03-08
CN1071169A (zh) 1993-04-21
GR3032619T3 (en) 2000-05-31
PT533264E (pt) 2000-05-31

Similar Documents

Publication Publication Date Title
KR930006021A (ko) 궤양 억제제의 제조방법
KR840004712A (ko) 벤조퀴논 유도체의 제조방법
KR850006209A (ko) 피리디니오트리아지닐그룹과 비닐설폰형 그룹을 함유하는 섬유반응성 화합물의 제조방법
KR860003241A (ko) 피페리딘 유도체의 제조방법
KR850005845A (ko) 7-아미노-3-치환된-메틸-3-세펨-4-카복실산 및 그의 저급 알킬실릴 유도체의 제조방법
KR850004754A (ko) 3-인돌 카르복사미드 화합물류의 제조방법
KR860001065A (ko) 4-아세톡시-3-히드록시에틸아제티진-2-온유도체의 제조방법
KR830010039A (ko) 페닐 지방성 카복실린산 유도체의 제조방법
KR860002502A (ko) 1,3-옥사졸리딘-2-온 유도체의 제조방법
KR850006395A (ko) 글리시딜 화합물의 제조방법
KR890000490A (ko) 복소다환식 방향족 화합물
KR840007556A (ko) 방향족 히드록시카르복시산 벤질 에스테르의 제조방법
KR920002572A (ko) 로다민류의 제조방법
KR880011114A (ko) 치환된 아세틸렌 화합물의 제조방법
SE7811761L (sv) 4,5,6,7-tetrahydroimidazo-(4,5-c),pyridinderivat och forfarande for deras framstellning
KR870003114A (ko) 테트라하이드로이소퀴놀린 유도체
KR850002095A (ko) 4,7-디히드로피라졸로[3,4-b] 피리딘 유도체의 제조방법
KR880005095A (ko) 2,4-디아미노-3-옥시-피리미딘 유도체의 제조방법
KR920009841A (ko) 6-(3-디메틸아미노프로피오닐)포르스콜린 제조방법
KR850006397A (ko) 치환된 이소크로만 및 옥세핀의 제조방법
KR890017257A (ko) 세팔로스포린 화합물의 제조방법
KR850007425A (ko) 세팔로스포린 유도체와 이의 염의 제조방법
KR920002534A (ko) 16-하이드록시-16메칠pge계 프로스타글란딘 유도체의 제조방법
KR910007914A (ko) 벤즈이미다졸 유도체의 신규한 제조방법
KR830002724A (ko) 벤즈이미다졸 유도체의 제조방법

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
G170 Re-publication after modification of scope of protection [patent]
FPAY Annual fee payment

Payment date: 20071005

Year of fee payment: 9

LAPS Lapse due to unpaid annual fee